GlassScriptPhysician profile
Benjamen Williams
NPI 1255416558
$3,106.92
in general payments reported to CMS, 2019-2025
24 companies · $940 in 2025
The $940 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.33 · 2021: $101 · 2022: $51.41 · 2023: $1,129 · 2024: $857 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.91 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $500.16 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $273.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $253.47 | 2023-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $203.42 | 2023-2024 | Freestyle Libre |
| Glaxosmithkline, LLC. | $198.49 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $187.06 | 2023-2025 | Repatha, Evenity, Otezla |
| Exact Sciences Corporation | $105.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.74 | 2023-2025 | Xifaxan |
| Pfizer INC. | $92.51 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.60 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $63.82 | 2023-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $46.95 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $46.29 | 2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $46.24 | 2023-2024 | Linzess |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.58 | 2025 | Watchman Flx |
| Axsome Therapeutics, INC. | $36.60 | 2024 | Auvelity |
| Allergan, INC. | $29.33 | 2020 | |
| Dynavax Technologies Corporation | $22.93 | 2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $20.02 | 2025 | |
| Idorsia Pharmaceuticals US INC | $19.78 | 2023 | Quviviq |
| Dexcom, INC. | $17.85 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $17.10 | 2024 | |
| Protega Pharmaceutials INC | $16.92 | 2025 | Roxybond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamen Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.